Arvinas/$ARVN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Arvinas
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Ticker
$ARVN
Sector
Primary listing
Employees
430
Headquarters
Website
Arvinas Metrics
BasicAdvanced
$683M
-
-$0.81
2.47
-
Price and volume
Market cap
$683M
Beta
2.47
52-week high
$27.19
52-week low
$5.90
Average daily volume
2.5M
Financial strength
Current ratio
5.703
Quick ratio
5.62
Long term debt to equity
1.347
Total debt to equity
1.648
Profitability
EBITDA (TTM)
-98
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-18.73%
Operating margin (TTM)
-32.47%
Effective tax rate (TTM)
0.51%
Revenue per employee (TTM)
$730,000
Management effectiveness
Return on assets (TTM)
-6.30%
Return on equity (TTM)
-10.17%
Valuation
Price to revenue (TTM)
2.473
Price to book
1.33
Price to tangible book (TTM)
1.33
Price to free cash flow (TTM)
-2.344
Free cash flow yield (TTM)
-42.67%
Free cash flow per share (TTM)
-4.535
Growth
Revenue change (TTM)
93.85%
Earnings per share change (TTM)
-81.94%
3-year revenue growth (CAGR)
35.05%
3-year earnings per share growth (CAGR)
-44.72%
What the Analysts think about Arvinas
Analyst ratings (Buy, Hold, Sell) for Arvinas stock.
Bulls say / Bears say
Vepdegestrant extended progression-free survival to five months, versus two months for AstraZeneca’s Faslodex, in patients with ESR1 mutations, showing superior results in a targeted group. (Reuters)
Out-licensing vepdegestrant along with cost reductions are expected to yield savings of over $100 million a year, boosting Arvinas’s balance sheet and prolonging its operating runway. (Reuters)
The board’s authorization of a $100 million stock buyback reflects management’s confidence in Arvinas’s market value and alignment with shareholder interests. (Reuters)
Arvinas will reduce its workforce by an additional 15% on top of a 33% cut earlier in the year, signaling potential challenges in execution and risk of losing key talent. (Reuters)
Arvinas shares fell 3.4% in after-hours trading following the strategic update, pointing to investor doubts about the company’s new direction. (Reuters)
By transferring commercialization rights for its lead breast cancer candidate, Arvinas gives up control and limits its potential gains from future sales. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 8 Nov 2025.
Arvinas Financial Performance
Revenues and expenses
Arvinas Earnings Performance
Company profitability
Arvinas News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arvinas stock?
Arvinas (ARVN) has a market cap of $683M as of November 09, 2025.
What is the P/E ratio for Arvinas stock?
The price to earnings (P/E) ratio for Arvinas (ARVN) stock is 0 as of November 09, 2025.
Does Arvinas stock pay dividends?
No, Arvinas (ARVN) stock does not pay dividends to its shareholders as of November 09, 2025.
When is the next Arvinas dividend payment date?
Arvinas (ARVN) stock does not pay dividends to its shareholders.
What is the beta indicator for Arvinas?
Arvinas (ARVN) has a beta rating of 2.47. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.